Palvella Therapeutics, Inc. (PVLA) Gains from Investment Securities (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Gains from Investment Securities for 11 consecutive years, with -$843000.0 as the latest value for Q3 2024.
- On a quarterly basis, Gains from Investment Securities fell 1209.21% to -$843000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was -$788000.0, a 209.29% decrease, with the full-year FY2023 number at $16085.0, down 94.93% from a year prior.
- Gains from Investment Securities was -$843000.0 for Q3 2024 at Palvella Therapeutics, down from -$21000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $636000.0 in Q3 2020 to a low of -$843000.0 in Q3 2024.
- A 5-year average of -$43550.8 and a median of -$23500.0 in 2021 define the central range for Gains from Investment Securities.
- Peak YoY movement for Gains from Investment Securities: skyrocketed 957.14% in 2022, then plummeted 1209.21% in 2024.
- Palvella Therapeutics' Gains from Investment Securities stood at -$764000.0 in 2020, then soared by 107.33% to $56000.0 in 2021, then surged by 957.14% to $592000.0 in 2022, then plummeted by 97.28% to $16085.0 in 2023, then tumbled by 5340.91% to -$843000.0 in 2024.
- Per Business Quant, the three most recent readings for PVLA's Gains from Investment Securities are -$843000.0 (Q3 2024), -$21000.0 (Q2 2024), and $16085.0 (Q4 2023).